Acutaas accelerated CDMO peak to H2 FY27, delayed electrolyte Phase 2
Management pulled the CDMO revenue peak a full year earlier while slipping the electrolyte additive phase 2 by a quarter, with no explanation for either move.
What's new
- Q1 FY27 revenue Rs 330 cr, up 59% year-on-year.
- Battery chemicals plant completed trial run and started commercial supply.
- EBITDA margin at 34.3%, gross margin at 57.9%.
- PAT Rs 75 cr, up 70%; net cash Rs 314 cr.
Themes from the call
Demand
Pharma intermediates grew 76.5%; battery demand described as 'exceptionally strong' and capacity-constrained.
Margins
Gross margin expanded 200 bps to 57.9% on pharma mix; specialty margin at 24% dragged by commodity exit.
Capital allocation
Q1 capex Rs 56 cr; FY27 plan ~Rs 95 cr plus unannounced R&D and land spend.
Guidance watch
- Electrolyte additive Phase 2 now due end Q2 FY27, a one-quarter delay from prior guidance.
- CDMO peak revenue from four validated products pulled forward to H2 FY27 vs earlier FY28 guidance.
- FY27 revenue growth guided at 25%; CDMO Rs 1,000 cr target for FY28 reaffirmed.
- Battery capacity of 4,000 MT expected to be fully utilized in three years.
Risk flags
- Delayed Phase 2 capex could push back third electrolyte additive product ramp.
- Accelerated CDMO revenue timeline unexplained — execution risk if customer orders fall short.
- R&D molecule throughput cut from ~50 to 30-40 annually, narrowing pipeline breadth without comment.
- Working capital rose to 99 days from 91 days, driven by inventory.
Key quotes
-
"The Phase 2 which is for the third product of our electrolyte additive segment is going on schedule. As we mentioned earlier, by the end of Q2 FY27, we would be completing our capex."
— Acutaas management, Jul 2026 call -
"At a time when supply is already tight for us, this is not a passing phase; it is a structural shift."
— Naresh Patel, Chairman and Managing Director
The brief
Acutaas delivered a strong quarter — revenue up 59% to Rs 330 cr, EBITDA margin at 34.3%, and PAT at 22.7%. The battery chemicals plant is now in commercial supply, and pharma intermediates grew 76.5%. But the call contained three unexplained shifts that overshadow the operational strength. The most consequential is the CDMO revenue acceleration: management moved the peak for four validated products from FY28 to H2 FY27, a full-year pull-forward with no elaboration. At the same time, the electrolyte additive Phase 2 capex slipped by a quarter, from Q1 to Q2 FY27, despite being called 'on schedule'. And the R&D pipeline throughput was revised down from about 50 molecules a year to 30-40, without acknowledgement of the drop. These inconsistencies matter because Acutaas is selling a story of broad-based growth beyond its anchor CDMO product. Investors are being asked to trust timelines for three new engines (battery chemicals, electrolyte additives, and semiconductor materials) while the track record on communicating timelines has wobbled. The numbers this quarter are excellent, but the shifting goalposts on CDMO and R&D make the guidance harder to underwrite.
Acutaas is firing on multiple cylinders, but investors need clearer timelines and fewer unexplained shifts.